Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028828 · ClinicalTrials.gov registry record · Phase 2
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study of Hematologic Malignancies and Allogeneic Stem Cell Transplantation, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06028828 is a Phase 2 study of Hematologic Malignancies and Allogeneic Stem Cell Transplantation that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 60 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06028828, a Phase 2 study of Hematologic Malignancies and Allogeneic Stem Cell Transplantation, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- RADIATION Total Body Irradiation
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06028828
The ClinicalTrials.gov registry entry for NCT06028828 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Fludarabine is the first listed.
NCT06028828 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06028828 about?
NCT06028828 is a clinical study titled "Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation". This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
What is the current status of trial NCT06028828?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-09-11. Estimated completion is 2027-09.
What conditions does trial NCT06028828 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Allogeneic Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation.
What interventions are being tested in trial NCT06028828?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Total Body Irradiation (RADIATION).
Who is sponsoring clinical trial NCT06028828?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06028828 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RECRUITING · Phase 2
-
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RECRUITING · Phase 2
-
IVIG for Infection Prevention After CAR-T-Cell Therapy
RECRUITING · Phase 2
-
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Hematologic Malignancies
All registered trials for this condition
Allogeneic Stem Cell Transplantation
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.